Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
34.85
+0.47 (1.37%)
Feb 21, 2025, 4:00 PM EST - Market closed
Surmodics Employees
Surmodics had 389 employees as of September 30, 2024. The number of employees increased by 13 or 3.46% compared to the previous year.
Employees
389
Change (1Y)
13
Growth (1Y)
3.46%
Revenue / Employee
$322,488
Profits / Employee
-$37,036
Market Cap
498.22M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
SRDX News
- 16 days ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
- 19 days ago - Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries - Business Wire
- 23 days ago - Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - Business Wire
- 3 months ago - Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Business Wire
- 4 months ago - Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System - Business Wire
- 5 months ago - Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter - Business Wire
- 7 months ago - Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results - Business Wire
- 7 months ago - SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX - Business Wire